Skip to main content
Erschienen in: Tumor Biology 8/2014

01.08.2014 | Research Commentary

Refute the conclusion made by Jie et al. in “Prognostic role of microRNA-100 in various carcinomas: evidence from six studies”

verfasst von: Dali Chen, Yubin Zhou, Heng Du, Guowei Che

Erschienen in: Tumor Biology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Recently, we had the honor of reading a meta-analysis article published in Tumor Biology which was completed by Jie et al. Because of our interest in the correlations between microRNAs (miRs) and human cancer prognosis, we carefully read the entire article. Jie et al. put forward a standpoint that deregulation of miR-100 in cancerous tissues could significantly predict poor survival in various carcinomas. The pooled hazard ratio (HR) with 95 % confidence interval (CI) was 2.19 (1.49–3.24, p = 0.0007). The reliability of the meta-analysis is reciprocally higher than traditional and narrative reviews. Furthermore, the reliability is exclusively dependent on reference retrieval, incorporating eligible articles as comprehensive as possible, and proper and accurate data extraction. We found several critical errors in their meta-analysis, and its conclusion was unbelievable and might misguide readers. According to their statistical strategies, we also conducted a meta-analysis to reevaluate the relationship between deregulation of miR-100 and human cancer prognosis for rectification. The present studies are not powerful enough to demonstrate the prognostic role of miR-100 in human cancers, and thus, much more works are needed in this field.
Literatur
1.
Zurück zum Zitat Chen J, Zheng B, Wang C, Chen Y, Du C, Zhao G et al. Prognostic role of microRNA-100 in various carcinomas: evidence from six studies. Tumour Biol. 2013 [Epub ahead of print] Chen J, Zheng B, Wang C, Chen Y, Du C, Zhao G et al. Prognostic role of microRNA-100 in various carcinomas: evidence from six studies. Tumour Biol. 2013 [Epub ahead of print]
2.
Zurück zum Zitat Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer. 2012;12:369. doi:10.1186/1471-2407-12-369.PubMedCentralPubMedCrossRef Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer. 2012;12:369. doi:10.​1186/​1471-2407-12-369.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Peng DX, Luo M, Qiu LW, He YL, Wang XF. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep. 2012;27(4):1238–44.PubMedCentralPubMed Peng DX, Luo M, Qiu LW, He YL, Wang XF. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep. 2012;27(4):1238–44.PubMedCentralPubMed
5.
Zurück zum Zitat Feber A, Xi L, Pennathur A, Gooding WE, Bandla S, Wu M, et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg. 2011;91(5):1523–30.PubMedCentralPubMedCrossRef Feber A, Xi L, Pennathur A, Gooding WE, Bandla S, Wu M, et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg. 2011;91(5):1523–30.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang X, et al. Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol. 2012;7:159.PubMedCentralPubMedCrossRef Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang X, et al. Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol. 2012;7:159.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Liu J, Lu KH, Liu ZL, Sun M, De W, Wang ZX. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer. 2012;12:519.PubMedCentralPubMedCrossRef Liu J, Lu KH, Liu ZL, Sun M, De W, Wang ZX. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer. 2012;12:519.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Bai J, Guo A, Hong Z, Kuai W. Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia. Onco Targets Ther. 2012;5:213–9.PubMedCentralPubMed Bai J, Guo A, Hong Z, Kuai W. Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia. Onco Targets Ther. 2012;5:213–9.PubMedCentralPubMed
9.
Zurück zum Zitat Wang G, Chen L, Meng J, Chen M, Zhuang L, Zhang L. Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma. Int Urol Nephrol. 2013;45(2):373–9.PubMedCrossRef Wang G, Chen L, Meng J, Chen M, Zhuang L, Zhang L. Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma. Int Urol Nephrol. 2013;45(2):373–9.PubMedCrossRef
10.
Zurück zum Zitat Chen P, Zhao X, Ma L. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;383(1–2):49–58.PubMedCrossRef Chen P, Zhao X, Ma L. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;383(1–2):49–58.PubMedCrossRef
11.
Zurück zum Zitat Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Saudo A, Dall'Oglio MF, et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol. 2011;185(3):1118–22.PubMedCrossRef Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Saudo A, Dall'Oglio MF, et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol. 2011;185(3):1118–22.PubMedCrossRef
Metadaten
Titel
Refute the conclusion made by Jie et al. in “Prognostic role of microRNA-100 in various carcinomas: evidence from six studies”
verfasst von
Dali Chen
Yubin Zhou
Heng Du
Guowei Che
Publikationsdatum
01.08.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 8/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2157-9

Weitere Artikel der Ausgabe 8/2014

Tumor Biology 8/2014 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.